Cambridge, UK, 23 February 2017: Horizon Discovery Group plc (LSE: HZD), the world leader in the application of gene editing technologies, is hosting a site visit at its corporate headquarters for institutional investors today and for sell-side analysts on 1st March 2017.
The visits will include a tour of Horizon’s new headquarters following the consolidation of the Group’s Boston operations, which has created a world class Centre of Excellence in gene editing and cell biology, while also providing a significant contribution towards Horizon’s Path to Profit strategy.
During the visit, attendees will hear about the Group’s businesses, markets and strategy. No price sensitive information will be disclosed. The presentations will be available on the Group’s website on 2nd March 2017.
Hosting the events will be Dr. Darrin Disley, Chief Executive Officer; Richard Vellacott, Chief Financial Officer; Terry Pizzie, Head of Commercial; Dr. Chris Lowe, Head of Research Operations; and Chris Claxton, VP Investor Relations.